226 related articles for article (PubMed ID: 23469968)
1. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer.
Peddi PF; Hurvitz SA
Future Oncol; 2013 Mar; 9(3):319-26. PubMed ID: 23469968
[TBL] [Abstract][Full Text] [Related]
2. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
Krop I; Winer EP
Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
Barginear MF; John V; Budman DR
Mol Med; 2013 Jan; 18(1):1473-9. PubMed ID: 23196784
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab emtansine for HER2-positive advanced breast cancer.
Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
[TBL] [Abstract][Full Text] [Related]
6. A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.
Kashiwaba M; Ito Y; Takao S; Doihara H; Rai Y; Kanatani K; Takashima S; Masuda N
Jpn J Clin Oncol; 2016 May; 46(5):407-14. PubMed ID: 26917603
[TBL] [Abstract][Full Text] [Related]
7. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.
Lambert JM; Chari RV
J Med Chem; 2014 Aug; 57(16):6949-64. PubMed ID: 24967516
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
[TBL] [Abstract][Full Text] [Related]
9. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy.
Dhillon S
Drugs; 2014 Apr; 74(6):675-86. PubMed ID: 24659374
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Krop IE; Lin NU; Blackwell K; Guardino E; Huober J; Lu M; Miles D; Samant M; Welslau M; Diéras V
Ann Oncol; 2015 Jan; 26(1):113-119. PubMed ID: 25355722
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
Girish S; Gupta M; Wang B; Lu D; Krop IE; Vogel CL; Burris Iii HA; LoRusso PM; Yi JH; Saad O; Tong B; Chu YW; Holden S; Joshi A
Cancer Chemother Pharmacol; 2012 May; 69(5):1229-40. PubMed ID: 22271209
[TBL] [Abstract][Full Text] [Related]
13. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
14. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).
Diessner J; Bruttel V; Stein RG; Horn E; Häusler SF; Dietl J; Hönig A; Wischhusen J
Cell Death Dis; 2014 Mar; 5(3):e1149. PubMed ID: 24675467
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
LoRusso PM; Weiss D; Guardino E; Girish S; Sliwkowski MX
Clin Cancer Res; 2011 Oct; 17(20):6437-47. PubMed ID: 22003071
[TBL] [Abstract][Full Text] [Related]
16. The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.
Diéras V; Bachelot T
Target Oncol; 2014 Jun; 9(2):111-22. PubMed ID: 23852665
[TBL] [Abstract][Full Text] [Related]
17. [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].
Guerin M; Sabatier R; Gonçalves A
Bull Cancer; 2015 Apr; 102(4):390-7. PubMed ID: 25790739
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Van den Mooter T; Teuwen LA; Rutten A; Dirix L
Expert Opin Biol Ther; 2015 May; 15(5):749-60. PubMed ID: 25865453
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
Haddley K
Drugs Today (Barc); 2013 Nov; 49(11):701-15. PubMed ID: 24308017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
